Key insights
- Artiva Biotherapeutics reported positive Phase 2a clinical trial data for its AlloNK cell therapy in refractory rheumatoid arthritis, leading to a significant stock price increase. The company has aligned with the FDA on a registrational trial design. While the company has a strong balance sheet, it is burning through cash and is not expected to be profitable this year, suggesting caution for investors.
SAN DIEGO - Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) reported clinical data from ongoing trials evaluating its AlloNK cell therapy combined with rituximab for autoimmune diseases, according to a press release statement issued Thursday.
The company reported that 71% of refractory rheumatoid arthritis patients with at least six months of follow-up in its Phase 2a basket trial achieved an ACR50 response, a measure of disease improvement. The initial clinical dataset as of April 3, 2026 included 21 refractory RA patients with at least 12 weeks of follow-up, with 13 patients having six months of follow-up. Investors have responded enthusiastically to the clinical progress, with the stock delivering a 474% return over the past year and trading at $12.52, giving the company a market capitalization of $309 million.
The data combined results from Artiva’s company-sponsored Phase 2a basket trial and an investigator-initiated basket trial. Patients had a mean disease duration of 14.8 years, and 81% had failed two or more prior biologic or targeted synthetic disease modifying anti-rheumatic drugs.
Artiva stated it has aligned with the FDA on a single registrational randomized controlled trial design for AlloNK in refractory RA. The trial is expected to enroll approximately 150 RA patients who have had inadequate response to two or more biologic or targeted synthetic disease modifying anti-rheumatic drugs of distinct classes. Patients would be randomized 2:1 to receive AlloNK plus rituximab or rituximab alone, with ACR50 response at six months as the primary efficacy endpoint.According to InvestingPro data, the company holds more cash than debt on its balance sheet and maintains liquid assets that exceed short-term obligations. However, InvestingPro Tips indicate the company is quickly burning through cash and is not expected to be profitable this year. The platform’s Fair Value analysis suggests the stock may be overvalued at current levels. Investors can access 11 additional ProTips and comprehensive analysis through the detailed Pro Research Report available for ARTV.
The company reported no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or treatment discontinuations due to adverse events in autoimmune patients treated with AlloNK. The Grade 3 or higher infection rate was 2%.
More than 70 autoimmune patients have been treated with AlloNK across more than 40 active clinical sites, primarily in community settings. Artiva expects to initiate the registrational trial in the second half of 2026 and report primary efficacy data in the second half of 2028.
In other recent news, Artiva Biotherapeutics reported its fourth-quarter results, which led Cantor Fitzgerald to reiterate an Overweight rating with a $10.00 price target on the company’s stock. The firm maintained its outlook after Artiva confirmed the timeline for initial clinical data for its AlloNK plus Rituxan regimen, targeting refractory rheumatoid arthritis patients, expected in the first half of 2026. Additionally, Artiva Biotherapeutics announced the appointment of Thad Huston as Chief Financial Officer, effective February 18. Huston, with over 30 years of experience in finance and business development, previously held senior roles at Galapagos NV, Kite Pharma, LivaNova PLC, and Johnson & Johnson.
In another development, Artiva Biotherapeutics appointed Elaine Sorg to its Board of Directors as a Class I director, with her term set to expire at the 2028 annual meeting of stockholders. Sorg, a seasoned executive with over 35 years in the biopharmaceutical industry, has previously led the commercialization of immunology therapies, including HUMIRA and RINVOQ. The company stated that there are no arrangements or transactions involving Sorg that require disclosure under regulatory guidelines. These recent developments highlight Artiva’s strategic moves in leadership and board composition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.